Editorial: A new look at the eye: Aldosterone and mineralocorticoid receptors as novel targets in retinal vasculopathy

Circulation Research

Volumn 104, Issue 1, 2009, Pages 9-11

  Touyz, Rhian M ^a   Callera, Glaucia E ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Angiogenesis; G6PD; Nox4; Spironolactone

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; BEVACIZUMAB; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; MINERALOCORTICOID RECEPTOR; PEGAPTANIB; RANIBIZUMAB; RENIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASCULOTROPIN A;

DIABETIC RETINOPATHY; EDITORIAL; HUMAN; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA DISEASE; RETINA NEOVASCULARIZATION; VASCULAR DISEASE; ANIMAL; CAPILLARY PERMEABILITY; CATTLE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NOTE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA VASCULITIS;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CAPILLARY PERMEABILITY; CATTLE; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEMS; HUMANS; NADPH OXIDASE; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; RABBITS; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, ALDOSTERONE; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; RETINAL VASCULITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59649109530     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.191288     Document Type: Editorial

References (22)

1. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res. 2009;104: 124-133.
2. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89-100.
3. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27:331-371.
4. Josifova T, Schneider U, Henrich PB, Schrader W. Eye disorders in diabetes: potential drug targets. Infect Disord Drug Targets. 2008;8: 70-75.
5. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res. 1998;82:619-628. (Pubitemid 28129033)
6. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem. 2001;276:43836-43841.
7. van Wijngaarden P, Qureshi SH. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin Exp Optom. 2008;91: 427-437.
8. Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med. 2008;86:615-621.
9. Wilkinson-Berka JL. Prorenin and the (pro)renin receptor in ocular pathology. Am J Pathol. 2008;173:1591-1594.
10. Wilkinson-Berka JL. Diabetes and retinal vascular disorders: role of the renin-angiotensin system. Expert Rev Mol Med. 2004;6:1-18.
11. Chen P, Scicli GM, Guo M, Fenstermacher JD, Dahl D, Edwards PA, Scicli AG. Role of angiotensin II in retinal leukostasis in the diabetic rat. Exp Eye Res. 2006;83:1041-1051.
12. Satofuka S, Ichihara A, Nagai N, Tsubota K, Itoh H, Ishida S. Pathologic roles of prorenin and (pro)renin receptor in the eye. Front Biosci. 2008; 13:3884-3895.
13. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372:1394-1402.
14. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372: 1385-1393.
15. Vaajanen A, Luhtala S, Oksala O, Vapaatalo H. Does the renin-angio-tensin system also regulate intra-ocular pressure? Ann Med. 2008; 10:1-10.
16. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care. 2008;31:S170-S180.
17. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007; 13:189-197.
18. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol. 2008;28: 1511-1518.
19. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008;266: 37-52.
20. von Lohneysen K, Noack D, Jesaitis AJ, Dinauer MC, Knaus UG. Mutational analysis reveals distinct features of the Nox4-p22phox complex. J Biol Chem. 2008;283:35273-35282.
21. Al-Shabrawey M, Rojas M, Sanders T, Behzadian A, El-Remessy A, Bartoli M, Parpia AK, Liou G, Caldwell RB. Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci. 2008;49: 3239-3244.
22. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology. 2004;145:4796-4802.